key: cord-0828971-71qr5xt6
authors: Zeng, Qing‐Lei; Li, Guang‐Ming; Ji, Fanpu; Ma, Shu‐Huan; Zhang, Guo‐Fan; Xu, Jiang‐Hai; Lin, Wan‐Bao; Xu, Guang‐Hua; Zhang, Guo‐Qiang; Li, Guo‐Tao; Cui, Guang‐Lin; Liu, Na; Zeng, Fan‐Jun; Ai, Zhi‐Guo; Xu, Guang‐Feng; Liu, Na; Liang, Jie; Zhang, Min‐Min; Li, Cheng; Zhang, Zhi‐Hao; Wang, Ze‐Shuai; Li, Zongfang; Yu, Zu‐Jiang
title: Clinical course and treatment efficacy of COVID‐19 near Hubei Province, China: a multicentre, retrospective study
date: 2020-06-12
journal: Transbound Emerg Dis
DOI: 10.1111/tbed.13674
sha: 5b3a5a9508eb52f7e0c740104d3c9a62702e5698
doc_id: 828971
cord_uid: 71qr5xt6

Currently, COVID‐19 has been reported in nearly all countries globally. To date, little is known about the viral shedding duration, clinical course, and treatment efficacy of COVID‐19 near Hubei Province, China. This multicentre, retrospective study was performed in 12 hospitals in Henan and Shaanxi Provinces from January 20 to February 8, 2020. Clinical outcomes were followed up until March 26, 2020. The viral shedding duration, full clinical course, and treatment efficacy were analysed in different subgroups of patients. A total of 149 COVID‐19 patients were enrolled. The median age was 42 years, and 61.1% (91) were males. Of them, 133 (89.3%) had fever, 131 of 144 (91%) had pneumonia, 27 (18.1%) required intensive care unit (ICU) management, 3 (2%) were pregnant, and 3 (2%) died. Two premature newborns were negative for SARS‐CoV‐2. In total, the median SARS‐CoV‐2 shedding period and clinical course were 12 (IQR: 9‐17; mean: 13.4, 95% CI: 12.5, 14.2) and 20 (IQR: 16‐24; mean: 21.2, 95% CI: 20.1, 22.3) days, respectively; and ICU patients had longer median viral shedding periods (21 [17‐24] vs 11 [9‐15]) and clinical courses (30 [22‐33] vs 19 [15.8‐22]) than non‐ICU patients (both p<0.0001). SARS‐CoV‐2 clearances occurred at least 2 days before fatality in 3 non‐survivors. Current treatment with any antiviral agent or combination did not present the benefit of shortening viral shedding period and clinical course (all p>0.05) in real‐life settings. In conclusion, the viral shedding duration and clinical course in Henan and Shaanxi Provinces were shorter than those in Hubei Province, and current antiviral therapies were ineffective for shortening viral shedding duration and clinical course in real‐world settings. These findings expand our knowledge of the SARS‐CoV‐2 infection and may be helpful for management of the epidemic outbreak of COVID‐19 worldwide. Further studies concerning effective antiviral agents and vaccines are urgently needed.

In December 2019, a novel coronavirus infection was first reported in Wuhan of Hubei Province, China, and then a public health emergency of international concern was declared by the World Health Organization (WHO) C. Wang, Horby, Hayden, & Gao, 2020; F. S. Wang & Zhang, 2020; Zhu et al., 2020) . Recently, the 2019 novel coronavirus was named "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV, 2020). SARS-CoV-2 is a positive-sense single-stranded RNA virus belonging to the genus Betacoronavirus. It is an enveloped, round or oval-shaped particle, and the polymorphism of the virus is commonly observed; and has been assigned to an existing species of hundreds of known viruses largely isolated from bats (Decaro & Lorusso, 2020) . Currently, SARS-CoV-2-associated disease has been named "coronavirus disease 2019 " by the WHO (WHO, 2020c) , and it has been reported in almost all countries worldwide and characterized as a pandemic by the WHO (WHO, 2020b) . Unfortunately, no effective drugs are clinically approved by the authorities globally because of the absence of evidence (Holshue et al., 2020; Kim et al., 2020) .

It is known that some COVID-19 patients have developed severe pneumonia, acute respiratory distress syndrome (ARDS), shock, or multiple organ failure (Chen et al., 2020; Huang et al., 2020; D. Wang et al., 2020) . Of them, 23-32% required admission to the intensive care unit (ICU) and 4.3-15% died (Chen et al.,

This article is protected by copyright. All rights reserved 2020; Huang et al., 2020; D. Wang et al., 2020) . Recently, several studies have described the epidemiological and clinical characteristics of patients from Wuhan City (Chen et al., 2020; Huang et al., 2020; D. Wang et al., 2020) or far away from Hubei Province (Chang et al., 2020; Xu et al., 2020) . To date, there is no large-scale research to mainly focus on the viral shedding duration, clinical course, and treatment efficacy of COVID-19 patients near Hubei Province, especially Henan Province, which had the third and second largest numbers of total COVID-19 patients and fatalities as of March 23, 2020 in China, respectively (WHO, 2020a) . Since the patients near Hubei Province may represent second-and third-generation (wave) of infections, understanding these conditions of COVID-19 near Hubei Province may have important implications that will help to control further spread of the disease in China and worldwide.

This retrospective, multicentre, observational study includes COVID-19 patients from 12 centers in Henan and Shaanxi Provinces, China. According to the arrangements put in place by the local government, all suspected COVID-19 patients were admitted centrally to the designated local hospitals. Therefore, we retrospectively collected and analysed the epidemiological, clinical, laboratory, virological, management, and outcome data of patients with laboratory-confirmed SARS-CoV-2 infection.

Throat swab specimens from the upper respiratory tract were obtained from all suspected patients during their first visits to the hospital. Laboratory-confirmed COVID-19 was diagnosed according to WHO interim guidance (WHO, 2020d) . Laboratory confirmation of SARS-CoV-2 infection was performed in nine different Centers for Disease Control and Prevention (CDCs) of government, i.e., the CDCs of Henan and Shaanxi Provinces, the CDCs of Xinyang, Nanyang, Anyang, Shangqiu, Luoyang, and Hebi cities of Henan Province, and the CDC of Yan'an City of Shaanxi Province. The diagnostic reagents of RT-PCR

were provided by the four companies (Shanghai Huirui Biotechnology, Shanghai BioGerm Medical Biotechnology, Shanghai Geneodx Biotechnology, and Shanghai Zhijiang Biotechnology).

The aforementioned kits were all designed for the qualitative detection of SARS-CoV-2, and the results indicate the presence of SARS-CoV-2 RNA and can be used to support the diagnosis of SARS-CoV-2 infection. The SARS-CoV-2 specific primers and TaqMan probes in the reaction system are designed targeting the ORF1ab and N genes conserved in virus genome. After nucleic acid extraction from clinical specimens, one-step RT-PCR amplification is performed, and the fluorescence signal is detected; a real-time amplification curve is produced by the software system automatically. A set of human housekeeping gene specific primers and the corresponding probe are also included in the detection system as internal control, to avoid false negative caused by unqualified specimen collection, poor nucleic acid recover or failure of PCR.

Taking the kit of Shanghai BioGerm Medical Biotechnology as an example, the detailed protocols of RT-PCR were described as following. This kit is compatible with multi-channel fluorescence PCR instruments, such as ABI 7500 real-time PCR instrument. 1. Reagent preparation (in reagent preparation area). Thaw the RT-PCR Reaction Mix r, RT-PCR Enzyme Mix, and SARS-CoV-2 reaction mix at room temperature and spin briefly after mixing on a vortex mixer. Calculate the number of reactions (N) (N = number of specimens + 1 positive control + 1 negative control +1), and prepare the master mix according to the following table by adding to an appropriate volume of centrifuge tube. Spin the tube briefly after mixing completely and add 20 μl of master mix to required wells of plate or PCR tubes in PCR Clean Room. 2. Specimen processing (in specimen processing area). (1) Nucleic acid extraction: the specimens to be tested, positive control and negative control are processed according to the instructions of the nucleic acid extraction kit. (2) Adding specimens: add 5μl each of the nucleic acid of the specimens to be tested, positive control and negative control to the prepared PCR plates or tubes, and the final volume is 25μl/reaction. Cap the tubes or the plates securely and centrifuge tubes or plates to collect the liquid in the bottom immediately. 3. PCR amplification (in PCR amplification area). (1) Place the PCR reaction

This article is protected by copyright. All rights reserved tubes/plates in a fluorescent quantitative PCR instrument for amplification. (2) Cycling conditions: step 1 of reverse transcription (50℃, 10 min, 1 cycle), step 2 of pre-denaturation (95℃, 5 min, 1 cycle), step 3 of denaturation (95℃, 10 s, 40 cycles) and annealing/elongation/fluorescence detection (55℃, 40 s, 40 cycles).

4. Parameter setting for result analysis. Baseline setting: adjust the start and end values according to the post-amplification melting-curve analysis (It is recommended to set the start value at 3-15 and end value at 5-20. At the same time, adjust the negative control's amplification curve to be straight or below the baseline.), and click "Analysis" to obtain the analysis result automatically and review the results at the Report Interface. The test values of ORF1ab and N of the clinical specimens are determined using the ROC curve method with a cycle threshold of 38. Additionally, the limit of detection was 1×10 3 copies/ml, the positive/negative reference compliance rate within the company was 100%, and no cross-reaction with the known pathogens and reaction is not interfered by addition of interference substances.

Data were extracted from the electronic medical records and recorded in a pre-designed case report form.

We extracted epidemiological, demographic, clinical, laboratory, management, and outcome data from the relatively complete electronic medical records of patients in 12 centres from January 20 to February 8, 2020. Clinical outcomes were followed up until March 26, 2020. If data were missing from the records or if clarification was needed, we obtained data by direct communication with attending doctors or other health-care providers. All data were checked by three physicians.

The primary endpoints were SARS-CoV-2 shedding duration and full clinical course. The secondary endpoints were admission to the intensive care unit (ICU) and fatality. The SARS-CoV-2 shedding period indicates the duration from the first SARS-CoV-2 RNA positive result to the first SARS-CoV-2 RNA negative result. The full clinical course indicates the duration from the onset of illness to the second SARS-CoV-2 RNA negative result (the discharge timepoint for the majority of patients), discharge, or

This article is protected by copyright. All rights reserved fatality. The interval between the first and second SARS-CoV-2 RNA negative results was at least 48 hours.

The criteria for hospital discharge (recovery) were the same as those described by Lan et al (Lan et al., 2020) . Briefly, the criteria for hospital discharge were mainly based on the recovery of symptoms and signs, the clearance of SARS-CoV-2 RNA, and the absorption of lung inflammations (such as ground-glass opacities and/or consolidations). SARS-CoV-2 RNA clearance should be confirmed at least two times with an interval of more than 48 hours.

The study protocol was approved by the Institutional Review Commission of the The First Affiliated Hospital of Zhengzhou University, and the requirement for informed consent was waived by the Institutional Review Commission in light of de-identified data of patients and the urgent need to collect data.

Data sharing is not applicable to this article as no new data were created or analysed in this study. All available data (results) are presented in this article.

Continuous and categorical variables are presented as the median (interquartile range, IQR) and n (%), respectively. The Mann-Whitney U test, chi-squared test, or Fisher's exact test were used to compare the differences between various subgroups where appropriate. Analyses were carried out using SPSS statistical software, version 16.0 (IBM, Chicago, IL, USA). A p value of < 0.05 was set as the threshold for statistical significance.

This article is protected by copyright. All rights reserved

In total, 149 hospitalized COVID-19 patients were enrolled and analysed in this study. Of them, the median age of patients was 42 years (range 2-91), and 114 (76.5%) were 21-60 years old. There were 91 (61.1%) males and 3 pregnant women in this cohort. None of the patients had a history of exposure to the Huanan seafood wholesale market. Seventy-six (51%) patients had been to Hubei Province over the past two months before illness onset, and 35 (23.5%) had been exposed to laboratory-confirmed cases of COVID-19

despite not being to Hubei Province recently. Hypertension (24, 16.1%), chronic liver diseases (13, 8.7%), diabetes (11, 7.4%), cardiovascular diseases (8, 5.4%), and respiratory system diseases (5, 3.4%) were the most common comorbidities (Table 1) .

Overall, fever (133, 89.3%) was the most common symptom, followed by cough (95, 63.7%), fatigue (53, 35.6%), shortness of breath (37, 24.8%), dyspnoea (23, 15.4%), anorexia (20, 13.4%), and myalgia (18, 12.1%). Other symptoms included rigor, runny nose, diarrhoea, pharyngalgia, headache, nausea, chest pain, dizziness, vomiting, and haemoptysis (Table 1) . Ninety-five (63.7%) patients had three or more abovementioned signs or symptoms. Notably, 8 (5.4%) patients did not have any signs or symptoms, i.e., asymptomatic COVID-19 cases.

Of the 149 patients, leucocytes below the lower limit of the normal range were observed in 29 (19.5%) patients, and leucocytes above the upper limit of the normal range were recorded in 12 (8.1%) patients (Table 2 ). More than half of the patients (76/149) presented decreased lymphocytes to less than the lower limit of the normal range, and 12.9% (19/147), 15% (22/147 patients and the elevations of creatine kinase in 9 (6.1%) patients (Table 2) . Most patients (79.2%) had serum C-reactive protein (CRP) and erythrocyte sedimentation rates (ESRs) (70.1%) greater than the upper Accepted Article limit of the normal range (Table 2) . One (0.7%) patient had co-infection with Mycoplasma pneumonia, and 10 (6.7%) patients had the evidence of co-infection with bacteria on admission.

Of the 149 laboratory-confirmed cases, 13 (9%) of the 144 patients for whom chest CT scans were available patients did not have pneumonia manifestations on CT examinations on admission. Of the 131 (91%, 131/144) patients who had pneumonia imaging findings, 24 had unilateral pneumonia, 107 had bilateral pneumonia, 104 had multiple mottling and ground-glass opacity, and 4 patients had pleural effusion (Table 2) . Additionally, typical dynamic changes in a patient's chest CT images from admission to SARS-CoV-2 RNA clearance are presented in Figure 1 .

Of the 149 patients, 27 (18%) were admitted to the ICU within one week after hospitalization (Table 3) .

Compared with the 122 non-ICU patients, the 27 ICU patients had a higher proportion of patients aged more than 70 years (p < 0.0001); decreased lymphocyte count (p = 0.002); increased ESR, CRP and procalcitonin levels (all p values < 0.0001); and increased ALT and LDH levels on admission (both p values < 0.0001). Additionally, hyponatremia (p < 0.0001) and high serum D-dimer levels (p = 0.005) were more common in ICU patients than in non-ICU patients on admission. More ICU patients than non-ICU patients presented dyspnoea and respiratory rates of more than 24 breaths per minute on admission (both p values < 0.0001).

Two of three pregnant women were in the third stage of pregnancy. Both of them experienced foetal heart rate instability and possible foetal respiratory distress and required early delivery by caesarean section at the 30 th and 37 th weeks of gestation, respectively. Fortunately, two (with an interval of 48 hours) SARS-CoV-2 RNA negative results for throat swab samples were observed in both newborns. One pregnant patient developed ARDS, required invasive mechanical ventilation and ECMO treatment, and Accepted Article eventually died on day 33 after delivery. Her baby's chest CT showed pneumonia, and was uneventful recovery followed by close monitoring and supportive treatment.

For the management of the patients, 80 (58%) of 138 patients receiving treatment accepted antiviral treatment, including oseltamivir (75 mg every 12 hours, orally), interferon α (2-3 times every 24 hours, aerosol inhalation), or lopinavir and ritonavir tablets (500 mg twice daily, orally) alone or in combination ( 

As of March 6, 146 (98%) of patients were discharged, and 3 (2%) patients died (Table 4 ). The ages of the 3 patients who died were 79, 33, and 30 years, respectively. The 79-year-old female patient and the 33-year-old male patient had the comorbidities of coronary heart disease and fatty liver disease, respectively, and the 30-year-old woman was pregnant. The median SARS-CoV-2 shedding period and full clinical course were 12 (IQR: 9-17; mean: 13.4, 95% CI: 12.5, 14.2) and 20 (IQR: 16-24; mean: 21.2, 95% CI: 20.1, 22.3) days, respectively. The shortest and longest viral shedding durations were 5 and 35 days, respectively. The shortest and longest full clinical courses were 9 and 44 days, respectively.

The viral shedding duration and full clinical course in ICU patients were both significantly longer than those of non-ICU care patients (Table 5) . Notably, SARS-CoV-2 RNA clearance occurred at least two days

This article is protected by copyright. All rights reserved (2, 3, and 15 days, respectively) before death in the 3 patients who died. Additionally, compared with patients treated with supportive therapy, patients treated with any antiviral agent or combination had a similar viral shedding duration and full clinical course (Table 6) . Furthermore, compared with the supportive therapy group, no significant differences for the viral shedding duration and or full clinical course were observed after the division of the antiviral treatment group into the detailed antiviral agent(s) subgroups. Notably, we found that the SARS-CoV-2 RNA clearance was closely synchronized with or occurred earlier than the absorptions of lung inflammations (Figure 1 ) in the majority of patients, and a minority of patients had delayed absorptions of lung inflammations after SARS-CoV-2 RNA clearance.

The current study is the first large-scale, multicentre, observational cohort to solely focus on the In the current study, 18.1% (27/149) of patients required care in the ICU within one week after hospital admission, and 3 patients died. We observed that ICU patients had older age (55 vs 38 years); higher prevalence of dyspnoea (63% vs 4.9%); and higher levels of procalcitonin, CRP, ESR, LDH, and D-dimer on admission than non-ICU patients ( Table 3 ). The mortality rate of Henan Province is lower than that of Hubei Province (WHO, 2020a), although Henan Province is the province closest to Wuhan City. The reduced mortality rate may be attributed to the epidemiological characteristics of these patients. In the current study, none of the patients (0%; 0/149) were exposed to the Huanan seafood wholesale market, which was presumed as the initial infection source, and 49% (73/149) were not exposed to Hubei Province,

i.e., the majority of patients can be regarded as the second or even third generation or wave of patients.

Additionally, these patients who had not been to Hubei Province may have been infected by exposure to their COVID-19 family members or other patients with COVID-19, suggesting the person-to-person transmission route as described previously (Chan et al., 2020; Li et al., 2020) .

Notably, we found that the period of viral shedding of patients near Hubei Province was at least 12 (9-17) days (Table 4) , i.e., from the first available positivity date to the first negativity date. Additionally, the median full clinical course for COVID-19 patients was 20 (16-24) days. However, the ICU patients had longer periods of viral shedding and clinical courses than the non-ICU patients ( Table 5 ). The current results are different from those of a previous report in the Wuhan cohort, which indicated that the median duration of viral shedding was 20 days (IQR 17-24) in survivors (Zhou et al., 2020) . The most likely explanation is that the patients from the Wuhan cohort had more severe cases. However, it is important to note that the actual period of viral shedding may be longer than the current finding because the viral positivity timepoint may be as early as the incubation period or before their first visits or admissions to hospitals.

Additionally, SARS-CoV-2 RNA clearance developed at least 2 days before death in all 3 patients who died in the current study. This phenomenon is also different from the previous study (Zhou et al., 2020) , which indicated that SARS-CoV-2 was detectable until death in non-survivors. The cause of this difference is unknown. It is important to note that fatalities in the current study were caused by the gradually developed fatal complications beyond the pneumonia itself. Furthermore, all 3 patients who died had the specific conditions, i.e., the coronary heart disease, fatty liver diseases, and pregnancy, which may be the precipitating factors. Notably, only one was an older person, and the other 2 patients were only 33 and 30

years. This finding indicates that young COVID-19 patients also have a risk of fatality when they have some comorbidities or specific conditions.

Notably, we found that the viral shedding duration and full clinical course were similar in the antiviral treatment subgroup and the support therapy group (Table 6 ). The antiviral agents included oseltamivir, lopinavir/ritonavir, arbidol, peramivir, interferon α, and any combinations thereof. This result is consistent with the conclusion of the recent study by Cao et al (Cao et al., 2020) , i.e., no benefit was observed with

This article is protected by copyright. All rights reserved lopinavir/ritonavir treatment beyond standard care, which is similar to the supportive therapy in the current study. Therefore, future effective antiviral treatment studies are urgently needed.

SARS-CoV-2 leads to pneumonia and has various signs and symptoms, such as fever, cough, fatigue, or even dyspnoea (Carlos, Dela Cruz, Cao, Pasnick, & Jamil, 2020; Chen et al., 2020; Chung et al., 2020; Del Rio & Malani, 2020; D. Wang et al., 2020) . The current study has similar findings. Notably, we found that 10.7% (16/149) of laboratory-confirmed cases did not have fever, and eight patients did not have any signs or symptoms. Furthermore, 9% (13/144) of patients with available chest CT data did not have pneumonia presentations on chest CT scans. These patients with laboratory-confirmed SARS-CoV-2 infection with or without pneumonia and asymptomatic patients were diagnosed only because their family members had laboratory-confirmed cases, and they were then tested. These asymptomatic A previous study indicated that 43.4% (43/99) of patients had various degrees of liver injury, which was demonstrated by elevations of ALT or AST (Chen et al., 2020) . In the current study, we found that 19%

(28/147) of patients had increased ALT or AST levels in the laboratory-confirmed group. Eight patients had an explicit history of chronic liver diseases. Additionally, it is important to note that the majority of patients had a drug-taken history before admission, mainly including acetaminophen and traditional

Chinese medicines. These drugs may also cause liver injury. Therefore, the causality of SARS-CoV-2 and liver injury is largely unknown and needs further investigation.

The other feature of the current study is that this cohort covers all age groups of COVID-19 patients.

Notably, we found that eight children patients aged two to ten years old had mild signs or symptoms. Three children did not have fever, and the other three children had the sole symptom of diarrhoea. In contrast, among the older patients, 8 (29.6%) and 5 (4.1%) patients were aged more than 70 years in the ICU and non-ICU groups, respectively (p value < 0.001, Guan et al., 2020; Huang et al., 2020) . However, some other studies did not present explicit differences in sex susceptibility D. Wang et al., 2020) . It is important to note that the mobility for males is greater than that for females in China, especially for rural regions, and the male agricultural workers are always going outside for work, while females are always staying at home to take care of the family. Male mobility may increase the infection risk. Therefore, we suspected that the female sex itself may not play a protective role and that individuals may be widely susceptible to SARS-CoV-2 infection regardless of sex.

Additionally, we presented data from additional three pregnant women. Two women in the late stage of pregnancy required premature delivery, and one newborn had pneumonia and required care in the ICU.

Fortunately, the SARS-CoV-2 RNA results of the two newborns were all negative. It is largely unknown whether SARS-CoV-2 infection can contribute to premature delivery or intrauterine vertical transmission, and future studies are needed. The preliminary conclusion of the current study suggested that SARS-CoV-2 infection may be associated with premature delivery, but no evidence of mother-to-child transmission was found.

Our study has several limitations. First, only 149 patients were included in this multicentre, retrospective study in Henan and Shaanxi Provinces, and the findings may only indicate the characteristics of only these two provinces. Second, no recognized effective treatment has been given to patients, which may lead to the administration of various treatment regimens according to the previous SARS-CoV and MERS-CoV reports (Arabi et al., 2018; Chu et al., 2004; Falzarano et al., 2013; Groneberg et al., 2005;  Sheahan et al., 2020), or even empirical therapy for patients, and, eventually, these antiviral treatments proved ineffective in the current study. Furthermore, potential sources of bias may exist in this study.

However, it is known that Henan Province had the third largest number of SARS-CoV-2-infected patients in China (WHO, 2020a), and the majority of patients came from Xinyang, Zhengzhou, and Nanyang cities of Henan Province. In the current study, the vast majority of patients were from the largest designated local hospitals of the above three cities, which may avoid the potential sources of bias to the largest extent.

This article is protected by copyright. All rights reserved

In conclusion, to the best of our knowledge, we present the first data on the viral shedding period and complete clinical course of COVID-19 in a large cohort near Hubei Province, and these parameters were shorter than those in previous reports from cohorts in Wuhan City of Hubei Province. Additionally, SARS-CoV-2 clearance can occur at least two days before death, at least in three non-survivors of the current study. Furthermore, we first indicate that current antiviral treatments did not present the benefit of shortening the viral shedding period or the clinical course in real-world settings. These findings expand our knowledge of SARS-CoV-2 infection and may be helpful for the management of the epidemic outbreak of COVID-19 worldwide. Further studies concerning effective antiviral agents and vaccines are urgently needed.

The authors declare that they have no competing interests. Accepted Article 

Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques

Treatment and vaccines for severe acute respiratory syndrome

Clinical Characteristics of Coronavirus Disease 2019 in China

First Case of 2019 Novel Coronavirus in the United States

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Naming the 2019 Coronavirus

The First Case

Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures

Positive RT-PCR Test Results in Patients Recovered From COVID-19

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Glucocorticoids 25 (16.8%)

The authors would like to thank all participants and their families in the study. This study was supported by 

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved